There is substantial evidence that host genetic factors are important in determining susceptibility to infection with group A streptococci (GAS). Similar to humans, several studies have revealed that a genetic component may be important in determining susceptibility to GAS infection in mice. Thus, C3H/HeN mice are much more susceptible to streptococcal infection than BALB/c mice. We have determined here whether vaccination makes genetically susceptible mice as capable as genetically resistant mice to control GAS infection. Resistant BALB/c and susceptible C3H/HeN mice were immunized either systemically with heat-killed GAS or trough the mucosal route with an M protein-based subunit vaccine, and challenged with live bacteria. Vaccination elicited in both mouse strains similar levels of bactericidal anti-GAS IgG antibodies and also antigen-specific mucosal IgA.
Introduction
Group A streptococci (GAS; Streptococcus pyogenes) are common human pathogens capable of causing a variety of diseases, ranging from very mild infections (e.g. pharyngitis, tonsillitis or impetigo) to severe diseases associated with high mortality rates (e.g. necrotizing fascitiis, streptococcal toxic shock syndrome) [1] .
GAS has re-emerged as a public health threat due to the increased incidence of rapidly progressive severe infections observed since the mid-1980s worldwide [2] [3] [4] . Current control measures for treatment or prophylaxis for streptococcal diseases rely on chemotherapy [5, 6] .
However, there is a consensus that in the longer term, vaccination might constitute the most effective strategy to diminish the global disease burden caused by this pathogen. The development of an efficient anti-GAS vaccine is thus widely regarded as a major priority, but despite intensive research, a safe and effective anti-GAS vaccine is not yet available.
An important consideration for the design and implementation of vaccines is the understanding of the contribution of the host genetics to disease susceptibility because the population most in need of protection may be the one which is normally most susceptible to infection. In the particular case of GAS, several studies have shown that individuals within a single human population vary genetically in their susceptibility to infection with this pathogen [7] [8] [9] [10] . Thus, depending of the genetic makeup, different individuals will develop infections of different severities after encounter with the same streptococcal strain.
As a model for human variation, inbred mouse strains have been critical to our understanding of the role of host genetics in the susceptibility to group A streptococcal infection. Thus, strains of mice with various genetic backgrounds have been shown to differ markedly in their susceptibility to GAS [11, 12] . While some strains of mice (e.g. BALB/c) are very resistant to this pathogen, able to clear and survive the infection, other strains (e.g. C3H/HeN) are much more susceptible, allowing progressive bacterial multiplication, development of sepsis and death [11, 12] . exhibited a higher level of innate genetic resistance than others to infection with M. tuberculosis [13] . In that case, it was found that vaccination completely failed to make genetically susceptible mice as capable as genetically resistant mice to control infection with M. tuberculosis [14] . Therefore, genetically susceptible mice remained proportionally more susceptible to tuberculosis after vaccination than genetically resistant mice [14] .
The question addressed in this study is whether vaccination equally enables both genetically susceptible and resistant mouse strains to control GAS infection or, as it was the case of tuberculosis infection, susceptible mice remain proportionally much more susceptible to infection after vaccination than those exhibiting higher levels of innate resistance.
Materials and Methods

2.1.
Bacterial strains and growth conditions. S. pyogenes strain A20 (M type 23) is a human isolate obtained from the German Culture Collection (DSM 2071). The S. pyogenes strain KTL3 (serotype M1) is a blood isolated described previously [15] . Stocks were maintained at -70°C and were routinely cultured at 37°C in Todd-Hewitt broth (Oxoid, Basingstoke, UK), supplemented with 1% yeast extract for approximately 6 h. Bacteria were collected in mid-log-phase, washed twice with sterile PBS, diluted to the required inoculum and the number of viable bacteria determined by counting CFU after diluting and plating in blood agar plates (GIBCO) containing 5% sheep blood.
Mouse strains.
Inbred BALB/c, C3H/HeN and T cells-deficient BALB/c-nu female mice were purchased from Harlan-Winkelmann and used in experiments when they were between 8 and 10 weeks of age. Mice were housed in microisolators cage and given food and water ad libitum. All studies were approved by the appropriate ethical authorities.
Immunization protocols.
Mice were immunized intraperitoneally (i.p.) with 10 7 heatkilled GAS (HK-GAS) or intranasally (i.n.) with 20 µg of M1 protein. Animals were boosted with similar dose at day 7 and 14. Serum samples were collected and monitored for antigenspecific IgG antibodies previous to immunization and 2 weeks after the last boost. For lung lavage, mice were sacrificed 2 weeks after last boost and lung washes were collected after per tracheal cannulation, centrifuged at 3,000 x g for 5 min to remove debris and stored at -20°C.
Challenge protocols.
For protection studies, immunized and control mice were challenged with virulent GAS two weeks after the last boost. For intravenous challenge, mice were inoculated with 10 5 CFU of GAS in 0. 
Preparation of anti-GAS immune serum.
Groups of BALB/c and C3H/HeN mice were immunized intraperitoneally with 10 7 heat-killed GAS and boosted with similar dose at day 7 and 14. Serum samples were collected previously and 2 weeks after the last boost and used for the bactericidal assays.
Bactericidal assays.
A 50 µl of a bacterial suspension containing 5 10 3 CFU of GAS was mixed with 100 µl of heat-inactivated either pre-immune or anti-GAS serum and 400 µl of fresh, heparinized blood obtained from non-immune BALB/c or C3H/HeN mice. The blood was rotated for 3 h at 37°C, and viable counts were determined by plating diluted samples onto blood agar. Results are expressed as percentage of killing = [1 ! (mean CFU in the presence of anti-GAS serum)/(mean CFU in the presence of pre-immune serum)] × 100.
Passive transfer of immune serum.
To generate polyclonal immune serum, mice were intraperitoneally immunized with either 10 7 HK-GAS microorganisms or PBS as described above. Sera was pooled 10 days after the last boost and used for passive immunization. For passive protection, mice were injected intravenously with 300 µl of anti-GAS polyclonal immune or control serum 1h prior or 24h after bacterial inoculation.
Construction and purification of recombinant M1 protein. A full-length recombinant
M1 protein from GAS strain KTL3 was generated. Restriction and modifying enzymes were purchased from New England Biolabs, PCR reactions were performed using a proof-reading polymerase (GeneCraft) according to the manufacture's instructions. DNA manipulations were performed as described by Sambrook et al. [16] . 
Results
Humoral immune responses elicited in genetically susceptible C3H/HeN and
resistant BALB/c mice after systemic vaccination with HK-GAS. It has been suggested that the lack of anti-GAS opsonic antibodies constituted a risk factor towards the development of severe invasive GAS infections [17, 18] . Here, we have here compared the ability of mice previously shown to exhibit a natural resistance to GAS infection with that of mice highly susceptible to this pathogen to generate an anti-GAS systemic and mucosal antibodies after vaccination. To this end, resistant BALB/c and susceptible C3H/HeN mice were immunized i.p. with 10 7 HK-GAS strain A20 microorganisms or PBS, boosted at day 7 and 14, and the elicited anti-GAS IgG antibody response was measured 2 weeks after the last boost. GASspecific IgG antibodies were determined in serum by a whole cell ELISA. As shown in Fig.   1A , vaccination with HK-GAS elicited comparable high levels of anti-GAS IgG antibodies in both genetically resistant and susceptible mouse strains.
In order to determine whether differences in the genetic background of the mouse strain may influence the bactericidal capacity of the anti-GAS antibodies elicited after vaccination, BALB/c and C3H/HeN mice were vaccinated with HK-GAS strain A20 and the bactericidal capacity of the elicited anti-GAS antibodies was evaluated using the whole blood assay described in the Materials and Methods section. Results in Fig. 1B show that antibodies elicited after vaccination with HK-GAS strain A20 induced more than 90% mean reduction against the homologous strain (A20) in both mouse strains. These results demonstrate that vaccination induced in both, resistant and susceptible mice, anti-GAS bactericidal antibodies.
That bacterial reduction was due to antibody-mediated opsonizing killing and not to bacterial aggregation by specific antibodies was demonstrated by performing a previously described assay [19] . Briefly, 5 10 3 CFU of GAS strain A20 was added to serum isolated from either GAS-vaccinated BALB/c or C3H/HeN mice or non-immune control mice and rotated for 3 h at 37°C. Viable bacteria were determined after incubation by plating serial dilutions onto blood agar. Similar number of viable bacteria were counted, independently of whether they were incubated with control or anti-GAS serum (data not shown). These results clearly indicate that specific anti-GAS antibodies did not aggregated streptococcal microorganisms in our experimental setting.
3.2.
Protective immune response against GAS elicited in genetically resistant and susceptible mice after vaccination. To test whether the immune response elicited after vaccination could make innate susceptible C3H/HeN mice as resistant to GAS as BALB/c mice, animals from both strains were immunized i.p. with 10 7 HK-GAS strain A20
microorganisms and boosted at day 7 and 14. Control animals received PBS. On day 28, mice
were intravenously challenged with a lethal dose of live homologous GAS (10 5 CFU) and the survival rates of animals was monitored overtime. As expected, both vaccinated and control resistant BALB/c mice survived GAS infection ( Fig. 2A) . In contrast, susceptible control C3H/HeN mice underwent a severe infection course, which eventually led to a fatal outcome in all the infected animals by day 3 after bacterial inoculation ( Fig. 2A) . On the other hand, HK-GAS-immunized susceptible C3H/HeN mice exhibited a level of resistance to GAS similar to that observed in control and vaccinated BALB/c mice (90% survival) ( Fig. 2A) .
That vaccination makes innate resistant and susceptible mice equally in their capacity to control GAS infection was further demonstrated by the lower bacterial loads in blood of both groups of vaccinated mice at day 2 after bacterial inoculation (p < 0.05, ANOVA test) (Fig. 2B ).
Mucosal immune responses elicited in genetically susceptible C3H/HeN and
resistant BALB/c mice after intranasal vaccination with a subunit vaccine. Group A streptococcus can very efficiently colonize the mucosal surface of the upper respiratory tract.
Therefore, in addition to the systemic immune response, an antigen-specific mucosal immune responses is also required to achieve full protection against the wide spectrum of streptococcal diseases. This is clearly evidenced by the fact that antigen-specific secretory
IgA is required for prevention of pharyngeal GAS infection [20, 21] .
It is generally accepted that while systemic vaccination only induced systemic immune responses, vaccination through the mucosal route can induce both mucosal and systemic immune mechanisms [22, 23] . Therefore, we next determine the ability of both resistant BALB/c and susceptible C3H/HeN mice to produce anti-GAS specific IgA mucosal antibodies after intranasal immunization with M1 protein as model of subunit vaccine. The selection of a M1 protein for these experiments is based on the fact that the M1 is one of the most commonly isolated serotype from patients with GAS infections [24, 25] . Mice were immunized i.n. with 20 µg of M1 protein, boosted at day 7 and 14 after the last boost, and the level of anti-M1 IgA antibodies was determined in the lung mucosa at day 28 after the first immunization. Results in Fig. 3A show that mucosal vaccination elicited comparable levels of anti-M1 IgA antibodies in both resistant BALB/c and susceptible C3H/HeN mice.
The ability of anti-M1-specific mucosal antibodies elicited after intranasal vaccination to control bacterial growth after mucosal infection was next evaluated. Vaccinated and control BALB/c and C3H/HeN mice were challenged with GAS strain KTL3 (M-1 serotype) through the respiratory route. Bacterial loads in lungs were determined in the different groups of mice at day 2 after bacterial challenge. Significantly lower amount of bacteria were found in the lungs of vaccinated mice after challenge with virulent GAS of either the resistant or susceptible mouse strains when compared with control mice (p < 0.05; ANOVA text) (Fig.   3B ).
Bactericidal anti-GAS antibodies are T cells-dependent. Natural antibodies to toxins,
bacteria and viruses are present in the sera of normal, non-immunized humans and mice and they have been shown to play a critical role during infection by enhancing immunogenitiy and preventing pathogen dissemination to vital organs [26] [27] [28] [29] . In order to rule out a role of natural antibodies in the anti-GAS resistance expressed by BALB/c mice, passiveimmunization experiments were conducted using BALB/c mice as donors and C3H/HeN mice as recipients. Thus, C3H/HeN mice were injected intravenously with 300 µl of sera from control BALB/c mice followed 1 h later by intravenous challenge with 10 5 CFU of S.
pyogenes strain A20. C3H/HeN mice receiving the same volume of isogenic serum were used as control. The median survival times for C3H/HeN mice that received the serum from BALB/c mice did not differ significantly than that from the C3H/HeN mice that received isogenic sera (p = 0.26; Wilcoxon test) (Fig. 4A) . In contrast, C3H/HeNmice receiving serum from immunized BALB/c mice exhibited high levels of protection with 100% of mice surviving infection (Fig. 4A) . Thus, resistance of BALB/c mice to GAS seems not to be due to the presence of natural anti-GAS antibodies.
To further determine the nature of the anti-GAS protective antibodies elicited after We next investigated whether administration of polyclonal immune serum at 24 h postinoculation, a time point when bacteria have disseminated and infection is progressing, could rescue genetically susceptible mice from a fatal outcome. Results in Fig. 4C show that
Discussion
Several studies have shown that host genetic factors are critical in determining host susceptibility against GAS infection [7] [8] [9] [10] . Thus, while some individuals might respond to GAS infection with a mild disease, the same streptococcal strain can cause very severe invasive infection in more susceptible persons.
Severe invasive infections caused by group A streptococci such as necrotizing fascitis (flesh-eating bacterium) or streptococcal toxic shock syndrome have been reported with increased frequency in recent years [2] [3] [4] . The reasons for this resurgence of severe GAS infections remain unclear, however, an increased exposure of susceptible individuals after decreased herd immunity due to infrequent exposure to GAS may have contributed to this remarkable rise of severe cases. In fact, several studies have suggested that low levels of isolate-specific as well as superantigen-neutralizing antibodies in infected individuals may increase the risk to develop invasive GAS disease [17, 18, 30, 31] . It is, therefore, plausible that the presence of a serotype-specific immune response elicited after vaccination might rescue genetically susceptible individuals for developing invasive disease after an encounter with this pathogen.
We have recently shown that the ability of different strains of mice to control infection with S. pyogenes was genetically determined [11, 12] . Thus, different strains of mice exhibit differential susceptibility to GAS infection, with some strains (e.g. BALB/c) being considerable more resistant than others (e.g. C3H/HeN). In the study presented here we have assessed whether vaccination equally enables both genetically susceptible and resistant mouse strains to control GAS infection. Our results show that both genetically resistant and susceptible mouse strains generated an antigen-specific immune response against GAS after mucosal or systemic vaccination that makes both mouse strains equally capable to control GAS infection. Protective antibodies were T cell-dependent as clearly evidenced by the ability of immune serum from immunocompetent but not from T cell-deficient nu/nu mice to transfer immunity to naïve susceptible mice. Thus, it seems that the presence of bactericidal antibodies surpasses the compromised expression of innate genetic resistance exhibited by C3H/HeN mice to GAS.
Administration of polyclonal immune serum to infected C3H/HeN mice at 24h postinoculation, a time point when bacteria have disseminated and infection is progressing, resulted in only a slight attenuation of the severity of infection, extending the survival time of infected animals but failing to rescue them from death. The inability to achieve sterilizing protection after passive transfer at 24 h postchallenge may suggest that the amount of anti-GAS antibodies administered was insufficient against the amount of bacteria present in infected mice at this time of infection. These results suggest that efficient protection after vaccination could only be acquired by the elicitation of high levels of long-lasting anti-GAS specific antibodies.
The results obtained in this study show that vaccination enables both genetically resistance and susceptible mice with an equal capacity to control GAS infection, clearly indicating that resistance to GAS can largely be achieved in the innately susceptible hosts by vaccination. Therefore, the implementation of a functional streptococcal vaccine may significantly contribute to the reduction or elimination of severe cases of invasive streptococcal diseases. 
